Screening IVF embryos for common-disease risk scores is commercially available, but the predicted benefits are small, uncertain, and ethically contested.

Sources: [1]

Evidence standingEarly human
Key facts
Portal
Reproduction & Development
Stage
Commercially offered, contested
Evidence
Early human
Reversible
Irreversible
Reviewed
Jun 2026
Read time
7 min
Contents

Page status

Ancestry bias in scores · Overstated benefit versus uncertainty

Key takeaways

  • Polygenic embryo screening ranks embryos by statistical risk scores for common traits and diseases.
  • The expected gain per embryo is small and the predictions carry large uncertainty.
  • Ancestry bias, pleiotropy, and consent for a future person raise serious ethical concerns.

What is being sold

Some companies offer to score IVF embryos using polygenic risk scores and rank them by predicted risk for conditions or traits. Prospective parents are given a relative ranking to inform which embryo to transfer.

Polygenic scores are built from population studies and predict average differences across groups far better than they predict outcomes for a single individual, especially among the few embryos in one family.

Why the benefit is overstated

Selecting among a handful of sibling embryos shifts risk only slightly, and the estimate for any one embryo is uncertain. Scores trained largely on European-ancestry data transfer poorly to other populations, and variants linked to one trait often affect others in unpredictable ways.

Beyond the statistics, selecting embryos on complex traits raises consent, equity, and normalization concerns. Major genetics bodies have urged caution, noting the mismatch between marketing and evidence.

Open questions

  • Does embryo ranking produce any real-world benefit for the child?
  • How should marketing of uncertain predictions to parents be regulated?

Watchlist

Signals that would move this entry along the evidence scale.

Regulatory guidanceAncestry-diverse score validationPleiotropy and trait selection

Key terms

References

  1. Problems with using polygenic scores to select embryos. Turley et al., NEJM, 2021
    Analysis of the limited and uncertain benefit of polygenic embryo screening.

Cite this page

Future Human Atlas. “Embryo Selection and Polygenic Screening.” Last reviewed Jun 2026. https://future-human-wiki.vercel.app/articles/embryo-polygenic-screening

Suggest an edit